醋酸甲羟孕酮可作为促性腺激素释放激素拮抗剂的替代方案用于卵子捐赠:一项随机对照试验
该前瞻性随机对照试验将318名卵子捐赠者按1:1分为MPA组和GnRH拮抗剂组,比较卵巢反应和生殖结局。结果显示两组获卵数、内分泌谱及妊娠结局均无显著差异,MPA可推荐用于卵子捐赠的卵巢刺激。
要点
- MPA组与拮抗剂组获卵数相似(21.4±11.7 vs 21.2±9.2)。
- 两组种植率、临床妊娠率、活产率等均无统计学差异。
- MPA方案更患者友好,可作为GnRH拮抗剂的替代选择。
核心结论
- MPA方案获卵数、内分泌谱、可移植胚胎数及妊娠结局与GnRH拮抗剂相似。
- MPA可推荐用于卵子捐赠的卵巢刺激,因其更患者友好。
研究设计与样本
- 前瞻性随机对照试验,2017年10月至2019年6月进行,评估卵巢反应。
- 318名捐赠者随机1:1分组,获卵分配给364名受者。
- 主要结局为获卵数和MII卵数,次要结局包括早发LH峰、激素谱及受者妊娠结局。
主要发现
- 获卵数MPA组21.4±11.7,拮抗剂组21.2±9.2(均数差0.14;95%CI -2.233,2.517)。
- 重组FSH总剂量、刺激时长及血清和卵泡液内分泌谱两组相当。
- 两组均未观察到早发排卵。
- 种植率MPA组68.1% vs 拮抗剂组62%,临床妊娠率64.5% vs 57.8%,持续妊娠率55.4% vs 48.5%,活产率55.1% vs 48.5%,累积活产率73.8% vs 70.7%,均无统计学显著差异。
关键数值与推荐
- MPA组:从卵巢刺激开始每日口服10 mg MPA。
- 拮抗剂组:主导卵泡达13 mm时开始GnRH拮抗剂(加尼瑞克0.25 mg/日)。
- 两组均使用重组FSH刺激,优势卵泡成熟时用GnRH激动剂诱导排卵。
- 受者通常移植1枚胚胎。
临床怎么用
- 在卵子捐赠的卵巢刺激中,可考虑使用MPA替代GnRH拮抗剂。
- MPA方案口服给药,可能提高患者便利性。
- 需注意该结论基于特定人群和方案,应用时需结合个体情况。
局限性
- 受者生殖结局为回顾性分析。
- 研究在单一大学附属私立IVF中心进行。
- 样本量有限,可能不足以检测微小差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare ovarian response and reproductive outcomes in oocyte donors undergoing pituitary suppression with medroxyprogesterone acetate (MPA) versus those undergoing conventional treatment with a gonadotropin-releasing hormone (GnRH) antagonist. DESIGN: A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes. The reproductive outcomes of the recipients were retrospectively analyzed later. SETTING: A university-affiliated private in vitro fertilization center. PATIENT(S): We randomly divided 318 donors into 2 groups in a 1:1 ratio. The oocytes obtained were assigned to 364 recipients. One hundred sixty-one donors were treated with a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and 156 were treated with a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm). Transvaginal ultrasound was performed, and serum estradiol, luteinizing hormone, and progesterone levels were recorded during monitoring. The following additional parameters were analyzed: endocrine profile (in follicular fluid), number of metaphase II oocytes, and pregnancy outcome. INTERVENTION(S): The donors included in the study group were stimulated using recombinant follicle-stimulating hormone and MPA at 10 mg/day, simultaneously begun on cycle day 2 or 3. Ovulation was induced using a GnRH agonist when dominant follicles matured. A short protocol with ganirelix at 0.25 mg/day was used for the control group. Oocytes were assigned to the recipients, followed by routine in vitro fertilization procedures in which 1 embryo was usually transferred. MAIN OUTCOME MEASURE(S): The primary outcome measure was the numbers of oocytes and metaphase II oocytes retrieved. The secondary outcomes were the incidence of premature luteinizing hormone surge, serum and follicular fluid hormone profiles, and clinical pregnancy outcomes in the recipient group. RESULT(S): The number of oocytes retrieved was 21.4 ± 11.7 in the MPA group and 21.2 ± 9.2 in the antagonist group (mean difference 0.14; 95% confidence interval -2.233, 2.517). The total dose of recombinant follicle-stimulating hormone, duration of OS, and endocrine profiles of the serum and follicular fluids were comparable in the 2 groups. No early ovulation was observed in either group. No statistically significant differences with respect to implantation rate (68.1% in the MPA group vs. 62% in the antagonist group), clinical pregnancy rate (64.5% in the MPA group vs. 57.8 in the antagonist group), ongoing pregnancy rate (55.4% in the MPA group vs. 48.5% in the antagonist group), live birth rate (55.1% in the MPA group vs. 48.5% in the antagonist group), or cumulative live birth rate (73.8% in the MPA group vs. 70.7% in the antagonist group) were observed between the groups. CONCLUSION(S): The administration of MPA resulted in oocyte retrieval rates, endocrine profiles, viable embryo numbers, and pregnancy outcomes similar to those achieved with the GnRH antagonist. Therefore, MPA can be recommended for OS in oocyte donation because it permits a more patient-friendly approach. CLINICAL TRIAL REGISTRATION NUMBER: NCT03300960.
引用
- Giles J, Alama P, Gamiz P, et al. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial. Fertil Steril. 2021. PMID: 33814126. doi:10.1016/j.fertnstert.2021.02.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。